

**Media Contact:**

Christina Aplington  
Ballou PR for HRA Pharma  
+33 (0)1 4222 2410  
[christina@balloupr.com](mailto:christina@balloupr.com)

## **HRA Pharma Appoints Erin Gainer as CEO to Lead Company Through Next Phases of International Growth**

*Founder André Ulmann becomes Chairman*

**Paris, France – April 28, 2009** – HRA Pharma ([www.hra-pharma.com](http://www.hra-pharma.com)), a privately-held, European pharmaceutical company that designs products, devices and supporting services in reproductive health and endocrinology, announced today that executive director of research and development, Erin Gainer, has been appointed chief executive officer to lead the company through the next phases of its international growth. HRA Pharma's previous CEO and founder, André Ulmann, will assume the role of chairman of the company's supervisory board.

"HRA Pharma has always been buoyed by fresh ideas and dynamic project development in niche sectors, and the company is now embarking on an aggressive international growth strategy as we launch new products, multiply projects in phase III clinical trials and establish European affiliates to support these programs," said Dr. Gainer. "André has been a visionary figure not only in building a leading company in reproductive health, but in empowering millions of women to take better control of their own healthcare. I am honored to be taking over from André as CEO of HRA Pharma, and look forward to our continued collaboration on projects that will break new ground in untapped therapeutic needs and influence healthcare around the globe."

Dr. Gainer joined HRA Pharma in 2000 and has been member of its board since 2007. During this time, she defined, developed and managed the company's global R&D program, notably driving its lead product candidate, ulipristal acetate, which is slated to reach market later this year, as a new generation of emergency contraception under the brand name ella<sup>®</sup>/ellaOne<sup>®</sup>. She also managed cross-disciplinary pharmaceutical, preclinical and clinical development, regulatory affairs and marketing project teams, as well as collaborative projects with academic and industrial groups worldwide. With a background in trans-Atlantic public health, Dr. Gainer also ensured that the company's socially conscious approach to healthcare was applied to corporate and product development endeavours in developing countries.

Dr. Gainer, who has American and Irish citizenship, earned her bachelor's degree in biology and English from Rice University, her master's degree in public health from The Johns Hopkins University, her Ph.D. in epidemiology from the University of Paris XI and her Executive MBA from INSEAD. She is a member of the American Public Health Association, the European Society of Contraception, the American Society for Emergency Contraception, and the Healthcare Businesswomen's Association.

"Over the years, Erin's combination of international scientific and business backgrounds has been key to HRA Pharma's growth, and she is the natural choice to spearhead and implement new initiatives as CEO," added Dr. Ulmann.

###

**About HRA Pharma**

HRA Pharma is an emerging, privately-held European pharmaceutical company that designs products, devices and supporting services in niche areas of health and makes them available to doctors and patients worldwide. The company targets therapeutic gaps in the areas of reproductive health and endocrinology, and uses innovative marketing solutions and socially-conscious programs, such as contraception education in developing countries, to promote healthy management of drugs and diseases. A pioneer in emergency contraception, its product NorLevo was the first emergency contraceptive based on one type of progesterone to be approved for sale by health authorities. Headquartered in Paris, France and with offices in Bochum, Germany, HRA Pharma has built a strong network of R&D, manufacturing, distribution and NGO partners which enables it to satisfy critical patient needs and improve patient health in over 50 countries across the globe. Visit [www.hra-pharma.com](http://www.hra-pharma.com) for more information.